PubMed Verified All reconstitution & dosage charts sourced directly from published medical literature.
Academic Policy & Disclaimer
aPeptideDictionary

[Exemplar] Semaglutide Protocol (5 mg)

Published August 27, 2026 5 min read 5 mg 10 mg Writer Exemplar Clinical Data

Semaglutide Dosage Chart (5 mg Vial)

Semaglutide is a long-acting GLP-1 receptor agonist. In clinical research it slows gastric emptying, increases satiety signalling, and improves glucose-dependent insulin secretion. Because of its extended half-life, protocols are typically once weekly subcutaneous injections with slow titration.

This exemplar page is intentionally dense: it demonstrates every protocol section type your writers can use in the section builder. Replace numbers and wording with your editorial content after launch — keep the structure.

Concentration example used throughout: 5 mg peptide + 2 mL BAC water → 2.5 mg/mL (2,500 mcg/mL). On a U-100 syringe, 0.25 mg = 10 Units.

How to Reconstitute & Measure (Visual Guide)

Step-by-step reconstitution

Writers can mix titles, rich text, images, alerts, and lists inside one Contents section. Below is the pattern to copy for any peptide that needs a visual how-to.

Figure 1 — Powder vial → BAC water → swirl → draw dose
Figure 1 — Powder vial → BAC water → swirl → draw dose

Reconstitution checklist

  1. 1 Wash hands; wipe vial stopper with alcohol
  2. 2 Draw 2.0 mL bacteriostatic water into a sterile syringe
  3. 3 Inject water slowly down the vial wall — do not blast the powder cake
  4. 4 Gently swirl until clear; do not vigorously shake
  5. 5 Label vial with reconstitution date; refrigerate 2°C–8°C

Reading the U-100 syringe

Figure 2 — Example draw mark at 10 units (0.10 mL) for a 0.25 mg dose at 2.5 mg/mL
Figure 2 — Example draw mark at 10 units (0.10 mL) for a 0.25 mg dose at 2.5 mg/mL

Measurement tip

If a dose lands between marks on a 100-unit barrel, either use a 30-unit syringe (finer marks) or change BAC water volume so the draw hits a clean line. The Dosage Calculator section below is pre-filled for this vial.

Quick conversions for this exemplar vial

  • 0.25 mg weekly → 10 Units (0.10 mL)
  • 0.50 mg weekly → 20 Units (0.20 mL)
  • 1.00 mg weekly → 40 Units (0.40 mL)
  • Concentration: 2.5 mg/mL after 2 mL BAC water

Writer note

Images in Contents blocks can use the media library (image_id) or a direct URL (image_url). This exemplar uses theme SVG guides so it works without uploading media.

Standard / Gradual Titration Approach

Raise the weekly dose only if the previous step was tolerated for a full 4 weeks. Gastrointestinal effects in GLP-1 research are strongly dose-related — slower is usually better.

Titration timeline

Weeks 1–4

0.25 mg / week

Draw 10 Units (0.10 mL)

Weeks 5–8

0.5 mg / week

Draw 20 Units (0.20 mL)

Weeks 9–12

1.0 mg / week

Draw 40 Units (0.40 mL)

Maintenance*

1.7–2.4 mg / week

Recalculate — may need more water or larger vial

Dosing & Reconstitution Guide

Subcutaneous · once weekly · Half-life ≈ 7 days

Reconstitution Table (2 mL BAC water → 5 mg = 2.5 mg/mL)

Phase Daily Dose (mg) Units (per injection) (mL)
Phase Weekly Dose Units (U-100)
Start 0.25 mg 10 Units
Titrate 0.5 mg 20 Units
Step-up 1.0 mg 40 Units
High* 2.0 mg 80 Units

Frequency: Inject once weekly, same day each week, subcutaneously (abdomen, thigh, or upper arm). Rotate sites.

Math: concentration (mg/mL) = vial mg ÷ water mL. Units = (dose mg ÷ concentration) × 100.

For doses above ~1 mg at this concentration, verify the draw still fits the syringe you stock — or increase BAC water and rebuild the table.

Important: This exemplar is for educational / research framing only and is not medical advice. Match local regulatory language before publishing client-facing pages.

Dosage Calculator (Pre-filled for This Vial)

Defaults match this exemplar: 5 mg vial, 2 mL water, 250 mcg (0.25 mg) target dose. Writers: set these three fields per protocol so the syringe visual opens on the correct draw.

1

Reconstitution

Enter the peptide amount in the vial and the volume of bacteriostatic or sterile water you plan to add.

mg
mL
Concentration 5 mg/mL
Per 1 unit (0.01 mL) 50 mcg
Per 10 units (0.1 mL) 500 mcg
2

Your Dose

Enter the dose from your protocol and pick the insulin syringe you're using.

Syringe size

50-unit (0.5 mL): 1-unit marks. A good middle ground for draws of roughly 15–45 units.

3

Your Draw

Draw To
5 units
Volume
0.05mL
Doses / Vial
40
Vial Lasts
—
0 UNITS · U-100 SCALE
Lands exactly on the 5.0-unit mark.

Potential Benefits & Side Effects

Potential Benefits (research context)

  • Appetite reduction and lower energy intake in obesity trials
  • Improved glycemic markers in type 2 diabetes studies
  • Documented mean body-weight reduction with lifestyle support
  • Once-weekly schedule vs daily older GLP-1 analogues
  • Cardiovascular outcome data in labeled product programmes

Possible Side Effects

  • Nausea, vomiting, diarrhea — often early in titration
  • Constipation or abdominal discomfort
  • Injection-site reactions
  • Gallbladder-related events reported in some programmes
  • Labelled product warnings may include thyroid C-cell tumour risk in rodents — follow local regulatory framing

Storage Instructions

Lyophilized Powder

  • Short-term (<3 months): Refrigerate at 2°C–8°C
  • Long-term: Freeze at −20°C or lower
  • Protect from light and moisture
  • Allow vial to reach room temperature before opening to reduce condensation

Reconstituted Solution

  • Refrigerate at 2°C–8°C — do not freeze reconstituted solution
  • Use within 28 days when reconstituted with bacteriostatic water
  • Always use sterile technique when drawing doses
  • Discard if cloudy, discolored, or particulate matter appears

Supplies Needed

Example Cards section. Each card can use a media library image or a direct image_url. Button label is shared across all cards.

View Supply Notes
View Supply Notes
View Supply Notes
View Supply Notes

References

Wilding JPH et al. (2021)

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

View Source

Marso SP et al. (2016)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

View Source

Davies M et al. (2021)

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)

View Source

Important Note — Writer Exemplar

This page is a developer/writer exemplar. It shows every protocol section type with coherent Semaglutide-related sample data and visual guides. Replace copy with your expert-written content before treating it as a finished client page. Educational and research framing only — not medical advice.